About Us

About Us

Our mission is to serve our clients’ needs through timely, thorough, creative and innovative representation. Our clients and their employees are customers we appreciate and they deserve a salute, a smile and service that “wows” them.

Contact me, Bill Broydrick today at 414-719-1399, or billb@broydrick.com.

What’s the buzz …

Exact Sciences CEO Says Company Has “Attractive Long-Term Opportunity.”

Barron’s (5/2, Bary, 948K) reports that according to Exact Sciences CEO Kevin Conroy, there continues to be “big growth from the company’s colon-cancer test,” Cologuard. According to Barron’s, Exact Sciences “has successfully secured reimbursement from Medicare and most commercial insurers for the self-administered test.” Conroy says that Cologuard “could ultimately deliver revenue of $5 to $6 billion annually, more than 10 times projected 2018 sales, as physicians and U.S. consumers embrace it.” He said, “We have an attractive long-term opportunity given the size of the market and our position in it,” adding, “We’re still in the early innings.”

Exela CEO Dr. Phanesh Koneru Interviews President George W. Bush at Becker’s Healthcare Conference

We’re proud to welcome our newest clients:

Welcome to Client: Munger Farms

We are assisting Munger Farms in clarifying the current regulation on what constitutes  organic production. Munger is the largest blueberry grower in America based on the West Coast with locations in California, Oregon, and Washington

Update on Exact Sciences’ Cologuard and TRICARE

As of the most recent update to TRICARE’s preventive services policies, Exact Science’s Cologuard – the most effective, non-invasive colorectal cancer screening exam – is now given first-dollar coverage for 9.4 million active-duty, reserve, and National Guard personnel, veterans, and their dependents. The revision brings TRICARE into compliance with the most recent United States Preventive Services Task Force (USPSTF) colorectal cancer screening recommendations that include Cologuard as an A-rated option for preventive care. (Click heading to read more).

Exact Sciences’ Cologuard included in the NCQA’s HEDIS

As of two days ago Exact Sciences’ Cologuard – the most effective, non-invasive colorectal cancer screening exam – is now included in the National Committee for Quality Assurance’s (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS). Inclusion in HEDIS means that physicians will receive quality credit for providing patients an exam given an “A” rating by the United States Preventative Services Taskforce (USPSTF). Earning quality credits is part of the overall movement towards Value Based Purchasing (VBP) that entitles providers to bonuses based on quality improvement. We applaud NCQA for its decision, marking a reaffirmation of our nation’s commitment to fight colorectal cancer – the second leading cause of cancer deaths in America.

The decision marks yet another milestone for Cologuard on its path to nationwide, first-dollar coverage that already includes becoming the first product ever to simultaneously receive FDA approval and a Medicare coverage decision, A-rated by the USPSTF, and affirmed by Medicare Advantage.

EPA Announces Registration of Nanosilver Pesticide Product!

Congratulations to our client Poly-Technical Solutions, LTD!!

On Friday, EPA approved their application for a new nano-technology anti-microbial. It is a breakthrough innovation with wide applications and great commercial potential. Essentially it kills bacteria, fungi and viruses making clothing and many other materials including plastic self-cleaning.

Broydrick and Associates has represented them since December 2014. They first applied to EPA in 2009. We are happy and proud that we helped them win!

 

Read more on Bill’s Blog

Another Victory! Victory on Liver Donation Controversy

Wisconsin Physicians Service reverses decision on kidney treatment coverage

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave

SaveSave